Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa

Coyne, Ashlan J Kunz; Ghali, Amer El; Holger, Dana; Rebold, Nicholas; Morrisette, Taylor

doi:10.1007/s40121-022-00591-2

Cited by 137 publications

(83 citation statements)

References 121 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the last section of our work, the clinical-epidemiological threat posed by increasing rates of antibiotic resistance in P. aeruginosa and other species has been partially alleviated by the introduction of novel β-lactam–β-lactamase inhibitor combinations such as TOL-TAZ, CAZ-AVI, imipenem-relebactam, and others still in clinical development (e.g., meropenem-vaborbactam, meropenem-nacubactam, cefepime-taniborbactam, and cefepime-zidebactam [ 54 , 55 ]). Although these therapies displayed encouraging levels of effectiveness from the first moment, P. aeruginosa has repeatedly shown the capacity to develop resistance to CAZ-AVI and TOL-TAZ through different mechanisms, posing a real danger to the long-term efficacy of these drugs.…”

Section: Discussionmentioning

confidence: 99%

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa

et al. 2022

View full text Add to dashboard Cite

The growing antibiotic resistance of the top nosocomial pathogen Pseudomonas aeruginosa pushes research to explore new therapeutic strategies, for which the resistance-versus-virulence balance is a promising source of targets. While resistance often entails significant biological costs, little is known about the bases of the virulence attenuations associated with a resistance mechanism as extraordinarily relevant as β-lactamase production.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several molecular studies have revealed that increased efflux pumps are a popular and criticizing resistance mechanism in microbial biofilms [ 102 ]. This mechanism has been extensively studied in a commonly found biofilm-producing P. aeruginosa pathogen [ 103 ]. The PA1874-1877 (cluster of genes) involved in developing resistance in biofilms was discovered by Zhang and Mah.…”

Section: Resistance Mechanism In Biofilmsmentioning

confidence: 99%

Natural Strategies as Potential Weapons against Bacterial Biofilms

Asma

Imre

Morar

et al. 2022

Life

View full text Add to dashboard Cite

Microbial biofilm is an aggregation of microbial species that are either attached to surfaces or organized into an extracellular matrix. Microbes in the form of biofilms are highly resistant to several antimicrobials compared to planktonic microbial cells. Their resistance developing ability is one of the major root causes of antibiotic resistance in health sectors. Therefore, effective antibiofilm compounds are required to treat biofilm-associated health issues. The awareness of biofilm properties, formation, and resistance mechanisms facilitate researchers to design and develop combating strategies. This review highlights biofilm formation, composition, major stability parameters, resistance mechanisms, pathogenicity, combating strategies, and effective biofilm-controlling compounds. The naturally derived products, particularly plants, have demonstrated significant medicinal properties, producing them a practical approach for controlling biofilm-producing microbes. Despite providing effective antibiofilm activities, the plant-derived antimicrobial compounds may face the limitations of less bioavailability and low concentration of bioactive molecules. The microbes-derived and the phytonanotechnology-based antibiofilm compounds are emerging as an effective approach to inhibit and eliminate the biofilm-producing microbes.

show abstract

“…Carbapenem was once considered the most effective antibiotic for multidrug-resistant bacterial infections, but increasing resistance rates indicate that carbapenem-resistant organisms (CRO) have emerged as a frequent and challenging problem around the world [ 1 , 2 ]. CRO comprise lethal pathogens such as carbapenem-resistant Klebsiella pneumoniae (CRKP), Acinetobacter baumannii (CRAB) and Pseudomonas aeruginosa , resulting in increasing morbidity given the lack of safe and effective antibiotics [ 2 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Mortality Among Critical Acute Pancreatitis Patients with Carbapenem-Resistant Organism Infections and Drug Resistance of Causative Pathogens

Huang

Xiao

et al. 2022

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Carbapenem-resistant organisms (CRO) have emerged as a major global public health threat, but their role in critical acute pancreatitis (CAP) is still not defined. Our study aims to investigate risk factors associated with mortality and drug resistance among CAP patients with CRO infection. Methods The clinical characteristics of CAP patients with CRO infection and drug resistance of causative pathogens from January 1, 2016, to October 1, 2021, were reviewed retrospectively. Independent risk factors for mortality were determined via univariate and multivariate analyses. Result Eighty-two CAP patients suffered from CRO infection, with mortality of 60.0%. The independent risk factors for mortality were procalcitonin > 5 ng/L (hazard ratio = 2.300, 95% confidence interval = 1.180–4.484, P = 0.014) and lactic acid > 2 mmol/L (hazard ratio = 2.101, 95% confidence interval = 1.151–3.836, P = 0.016). The pancreas was the main site of infection, followed by lung, bloodstream and urinary tract. Klebsiella pneumoniae and Acinetobacter baumannii were the main pathogenic bacteria of CRO strains with extensive antibiotic resistance (> 60%) to 6 of 8 common antibiotics, except sulfamethoxazole (56.3%) and tigecycline (33.2%). Conclusion CRO infection has become a serious threat for CAP patients, with high rates of mortality. Procalcitonin and lactic acid represent two independent risk factors for mortality in CAP patients with CRO infection. Klebsiella pneumoniae and Acinetobacter baumannii are the primary categories of CRO pathogens. Greater efforts are needed for early prevention and prompt treatment of CRO infections in CAP patients. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-022-00624-w.

show abstract

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa

Cited by 137 publications

References 121 publications

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa

Natural Strategies as Potential Weapons against Bacterial Biofilms

Risk Factors for Mortality Among Critical Acute Pancreatitis Patients with Carbapenem-Resistant Organism Infections and Drug Resistance of Causative Pathogens

Contact Info

Product

Resources

About